PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could validate systemic efficacy against metastatic disease for the first time. Reportedly, Maxim Group maintains a $9 price target and strong buy rating, citing the company's growing clinical trajectory and RNAi platform validation. With a data readout expected this month, this could be a major catalyst for the company, as interest for innovative KRAS-targeting therapies continues to rise

PESG Research releases a new market update on Silexion Therapeutics (NASDAQ:SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models, a critical milestone that could continue to position its next-generation RNAi therapy at the forefront of KRAS-driven cancer treatment. With data analysis now underway and initial results expected in the coming weeks, according to the company's latest announcement, anticipation seems high for what could be a pivotal breakthrough, if indeed the data is positive.

A Potential Step Toward Transforming Pancreatic Cancer Treatment

Silexion's latest study could mark an important advancement in validating systemic administration of SIL-204. The study specifically assessed the therapy's ability to reduce primary tumor growth and inhibit metastatic spread in clinically relevant orthotopic pancreatic cancer models—providing a more accurate representation of human disease progression than traditional subcutaneous xenograft models.

Silexion's work with SIL-204 has already demonstrated compelling preclinical efficacy, including a 50% reduction in tumor growth and complete necrosis in half of treated tumors in previous systemic administration studies. Moreover, SIL-204 has shown sustained therapeutic levels for over 56 days from a single dose—an unprecedented achievement in RNAi-based therapies for KRAS-driven cancers.

Why This Matters: A Potential First for Metastatic Pancreatic Cancer

KRAS-driven cancers remain among the most aggressive and difficult-to-treat malignancies, particularly in pancreatic cancer, where over 90% of tumors harbor KRAS mutations. While other companies have attempted to target KRAS with small molecule inhibitors, Silexion's RNAi-based approach aims to silence multiple key KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D—offering a broader and potentially more effective therapeutic strategy.

The ability to target both primary and metastatic pancreatic cancer via systemic administration would represent a major breakthrough, as Silexion has not previously demonstrated this effect in metastatic models. If the orthotopic model results show significant impact on metastases, this could mark a critical validation step, potentially differentiating SIL-204 from existing KRAS-targeting approaches and opening the door to expanded clinical applications.

The industry seems to be closely watching Silexion's progress in light of the recent wave of multi-billion-dollar acquisitions in precision oncology. With major players like Pfizer acquiring Seagen for $43 billion and AbbVie purchasing Immunogen for $10.1 billion, the demand for novel cancer therapies seems to have increased in recent years. According to news reports, Maxim Group recently reaffirmed its strong buy rating on SLXN with a $9 price target, citing the company's strong clinical trajectory and the ongoing validation of its RNAi platform.

Upcoming Data Readout: A Potential Critical Catalyst

Silexion's announcement that initial results from the orthotopic model study will be released in March 2025 has sparked significant interest. If the data is positive, it could provide further confirmation of SIL-204's ability to target both primary and metastatic pancreatic cancer, marking the first time the company demonstrates systemic efficacy against metastatic disease.

If the upcoming results align with previous systemic administration findings and show significant impact on metastases, SIL-204 could emerge as a leading next-generation RNAi therapy for KRAS-driven cancers—potentially, in the future, reshaping the treatment paradigm for one of the deadliest malignancies.

Silexion Therapeutics has continued to execute on its strategy, pushing the boundaries of RNAi therapeutics for one of the most aggressive cancers. With data from the orthotopic pancreatic cancer study expected in March, many will likely be watching closely. If the upcoming results are positive and demonstrate impact on metastases, they could serve as a major catalyst for the company, potentially redefining its role in the precision oncology landscape.

Given the strong track record of preclinical success, increasing interest, and a competitive landscape ripe for M&A activity, Silexion Therapeutics is undoubtedly a company to watch in 2025.

Recent News from Silexion

• Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
• Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
• Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Silexion Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This alert has not been reviewed or approved by Silexion Therapeutics prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250303855379/en/

PESG Editorial Desk

[email protected]